Scientists develop a potential antibiotic from Komodo dragon blood
Komodo dragon blood may hold the key to tackling the “looming crisis” of antimicrobial resistance, according to scientists behind a potential new antibiotic, DRGN-6.
The synthetic molecule, developed by experts at George Mason University in the United States, was created by combining two genes found in Komodo dragon blood – an endangered species found on five Indonesian islands.
In preclinical tests DRGN-6 killed carbapenem-resistant Klebsiella pneumoniae, a highly drug resistant bacteria which causes a particularly aggressive form of pneumonia.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.